Linping Xu
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 5%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Immune cells in cancer
Papers in
- Oncology 17
- Cancer Immunotherapy and Biomarkers 6
- Co-authors
- Kongming Wu (6 shared papers)Ming Yi (6 shared papers)Suxia Luo (4 shared papers)Shuang Qin (2 shared papers)Shengnan Yu (2 shared papers)Mengke Niu (1 shared paper)Wei Li (8 shared papers)Anping Li (2 shared papers)
- Journals
- Frontiers in Oncology (2 papers)Genomics (2 papers)Molecular Pain (2 papers)Journal of Hematology & Oncology (2 papers)Journal of Translational Medicine (2 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Linping Xu
53 papers receiving 2.3k citations
Linping Xu's Hit Papers
Peers
Comparison fields: 5 of 118
- Oncology 1.1k
- Immunology 734
- Cancer Research 305
- Molecular Biology 662
- Pathology and Forensic Medicine 142
Countries citing papers authored by Linping Xu
This map shows the geographic impact of Linping Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linping Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linping Xu more than expected).
Fields of papers citing papers by Linping Xu
This network shows the impact of papers produced by Linping Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linping Xu. The network helps show where Linping Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Linping Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 Hit paper breakdown → | 2019 | 893 |
| 2 | Regulation of PD-L1 expression in the tumor microenvironment Hit paper breakdown → | 2021 | 462 |
| 3 | 2020 | 171 | |
| 4 | 2022 | 55 | |
| 5 | 2020 | 54 | |
| 6 | 2011 | 42 | |
| 7 | 2023 | 42 | |
| 8 | 2022 | 40 | |
| 9 | 2021 | 34 | |
| 10 | 2019 | 31 | |
| 11 | 2020 | 31 | |
| 12 | 2019 | 26 | |
| 13 | 2019 | 23 | |
| 14 | 2015 | 22 | |
| 15 | 2020 | 22 | |
| 16 | 2024 | 21 | |
| 17 | 2017 | 20 | |
| 18 | 2020 | 20 | |
| 19 | 2023 | 18 | |
| 20 | 2022 | 17 |
About Linping Xu
Linping Xu is a scholar working on Molecular Biology, Oncology, Immunology, Physiology and Genetics, having authored 55 papers that have together received 2.3k indexed citations. Recurring topics across this work include Pain Mechanisms and Treatments (8 papers), Immune Cell Function and Interaction (8 papers), Cancer Immunotherapy and Biomarkers (6 papers), Cancer-related molecular mechanisms research (5 papers), Cleft Lip and Palate Research (4 papers), Phagocytosis and Immune Regulation (4 papers), Immune cells in cancer (3 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Oncology (1.1k citations), Immunology (734 citations), Cancer Research (305 citations), Molecular Biology (662 citations) and Pathology and Forensic Medicine (142 citations). Linping Xu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Kongming Wu, Ming Yi, Suxia Luo, Shuang Qin, Shengnan Yu, Mengke Niu, Wei Li, Anping Li, Ying Jiao and Yongping Song. Their work appears in journals such as Frontiers in Oncology, Genomics, Molecular Pain, Journal of Hematology & Oncology and Journal of Translational Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.